Glycomet Trio 2/0.3 Tablet SR
By Glycomet Trio
Rx
10 Tablet SR in a Strip

Composition
Glimepiride(2mg) + Metformin(500mg) + Voglibose(0.3mg)

Manufacturer - USV Ltd
Arvind Vithal Gandhi Chowk, BSD Marg, Station Road, Govandi East, Mumbai - 400 088. , India.

Expires on or after
March, 2026

liver
When using Glycomet Trio 2/0.3 Tablet SR, it is important to be cautious if you have liver disease. Patients with liver issues may require a dose adjustment when taking this medication, so it's crucial to consult your doctor before starting treatment. Typically, Glycomet Trio 2/0.3 Tablet SR is initiated at a low dose for individuals with mild to moderate liver disease. However, it is not advised for use in patients with severe liver disease. Be sure to seek guidance from your healthcare provider to ensure the safe and appropriate use of Glycomet Trio 2/0.3 Tablet SR.

kidney
Glycomet Trio 2/0.3 Tablet SR may not be safe for patients with kidney disease. It is advised to avoid using this medication if you have kidney issues. Please consult your doctor before taking Provog GM Tablet SR, especially if you have severe kidney disease.

alcohol
It is not safe to drink alcohol while taking Glycomet Trio 2/0.3 Tablet SR.

driving
It is important to note that your driving ability may be impacted if you experience low or high blood sugar levels while taking Glycomet Trio 2/0.3 Tablet SR. It is advisable to avoid driving in such situations.

pregnancy
Glycomet Trio 2/0.3 Tablet SR may not be safe to use during pregnancy. Animal studies indicate potential harm to the baby's development. Your doctor will assess the risks versus benefits before prescribing. Consulting your doctor is advised.

breastfeeding
Glycomet Trio 2/0.3 Tablet SR is likely unsafe during breastfeeding as it may pass into breastmilk and harm the baby based on limited data.
Habit Forming | No |
Chemical Class | - |
Therapeutic Class | ANTI DIABETIC |
Action Class | - |
₹201.15
Inclusive of all taxes
Content verified by

Dr. Upasana Bhatia
MBBS - General Medicine
Last update on 01-Oct-2024